Business Context and Reporting Period
This Form 8-K Current Report was filed by Apogee Therapeutics, Inc. (Nasdaq: APGE) on July 7, 2025. The filing discloses significant clinical trial updates for the Company's pipeline, specifically focusing on APG777, an anti-IL-13 antibody for moderate-to-severe atopic dermatitis (AD), and APG279, a dual IL-13 + OX40L inhibitor.
Key Financial Metrics
This filing is a current report regarding clinical developments and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
APG777 Phase 2 APEX Trial (Part A) 16-Week Data
The Company announced positive 16-week data from Part A of the Phase 2 APEX trial, which enrolled 123 adult patients randomized 2:1 to APG777 versus placebo.
- Primary Endpoint: Met with a least squares mean percent change in EASI score of 71.0% reduction for APG777 versus 33.8% for placebo (p < 0.001).
- EASI-75 Response: 66.9% of APG777 patients achieved EASI-75 compared to 24.6% on placebo (p < 0.001), noted as the highest absolute and placebo-adjusted rate among biologics.
- Exposure-Response: Patients in the highest exposure quartile achieved an 89.5% EASI-75 response.
- Secondary Endpoints: vIGA 0/1 was 34.9% vs. 17.3% placebo (p < 0.05); EASI-90 was 33.9% vs. 14.7% placebo (p < 0.05).
- Itch Relief: Rapid onset observed with a 50.7% reduction in Itch NRS by Week 1 compared to 23.2% for placebo (p < 0.01).
- Safety: 56.1% of APG777 patients experienced treatment-emergent adverse events (TEAEs) vs. 63.4% placebo. Serious TEAEs were rare (1.2% vs. 2.4%). Discontinuation due to AEs was 2.4%. No injection site reactions were reported.
APG279 Phase 1b Trial Update
The Company announced that the first patient has been dosed in the Phase 1b head-to-head trial of APG279 versus DUPIXENT in moderate-to-severe AD. Readout is expected in the second half of 2026.
Guidance, Outlook, and Risks
Future Milestones
- APEX Part B: A dose optimization study with ~280 patients is ongoing. The 16-week readout is expected in mid-2026.
- APEX Part A Maintenance: Data on 3- and 6-month maintenance dosing is expected in the first half of 2026.
- Phase 3 and Commercialization: The Company anticipates initiating a Phase 3 trial of APG777 in 2026, with a potential commercial launch this decade, subject to regulatory alignment.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include the unpredictability of clinical trial results, the accuracy of cross-trial comparisons, regulatory approval timelines, and liquidity constraints. The Company explicitly disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the statistical significance and clinical relevance of the EASI-75 and EASI-90 results compared to current standard-of-care biologics.
- Confirm the enrollment status and projected timeline for the APEX Part B dose optimization study.
- Review the Company's cash runway and capital requirements to fund the anticipated Phase 3 trial initiation in 2026.
- Monitor the safety profile data, specifically regarding non-infective conjunctivitis and upper respiratory tract infections, as the patient population expands.
- Assess the regulatory strategy for the head-to-head Phase 1b trial of APG279 versus DUPIXENT.